Skip to main content
WAVERLEY PHARMA INC. logo

WAVERLEY PHARMA INC. — Investor Relations & Filings

Ticker · WAVE ISIN · CA94357L1058 LEI · 254900VT8CXPPV1G5Q51 TSXV Manufacturing
Open in API
Filings indexed 110 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CA Canada
Listing TSXV WAVE

About WAVERLEY PHARMA INC.

https://www.waverleypharma.com/

Waverley Pharma Inc. is a specialty biopharmaceutical company engaged in the research, development, and commercialization of safe, effective, and affordable therapeutics. The company primarily focuses on oncology, developing treatments such as poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer. Waverley Pharma commercializes its pharmaceutical products in markets including the United Kingdom, evidenced by successful tenders for drugs like Capecitabine with NHS Scotland. Furthermore, the company operates a retail pharmacy in the United States, integrating pharmaceutical innovation with direct patient service operations.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 92% confidence The document is a Form 52-109FV2 Venture Issuer Basic Certificate: a certifying officer’s attestation of the interim filings (interim financial report and interim MD&A). It does not contain actual financial statements or MD&A details, only an officer certification. Per the certification rule, such attestations should be classified as Regulatory Filings (RNS), not as the interim report itself.
2026-05-22 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate,” which is an officer certification of the interim filings (interim financial report and MD&A) rather than the interim report itself or any substantive financial data. Under the certification rule, such attestations should be classified as a general regulatory filing. Therefore, this falls under the Regulatory Filings (RNS) category.
2026-05-22 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 90% confidence The document is a Form 52-109FV2 venture issuer basic certificate signed by the CFO, certifying the interim financial report and MD&A. It does not contain the actual interim financial statements or substantive financial data, but rather is an officer’s attestation under NI 52-109. Per the certification rule, such attestations are classified as a regulatory filing rather than the interim report itself.
2026-05-22 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 92% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate,” which is an officer’s certification attesting to the interim filings (financial report and MD&A) for the period ended March 31, 2026. It does not contain actual financial statements or substantive interim results but is purely an attestation of those filings. Under the “CERTIFICATION RULE,” such officer certifications belong in Regulatory Filings (RNS), not as the interim report itself.
2026-05-22 English
Interim MD&A - English.pdf
Management Reports Classification · 95% confidence The document is a detailed Management Discussion and Analysis (MD&A) for the quarter ended March 31, 2026, providing management’s commentary on operations, results of operations, forward-looking statements, business strategy, project updates, and performance metrics. It does not include the full interim financial statements but references them, aligning with the definition of a Management Report (MDA) rather than a full Interim Report (IR) or announcement. Therefore, it should be classified as MDA.
2026-05-22 English
Interim MD&A - English.pdf
Management Reports Classification · 87% confidence The document is titled “Management Discussion and Analysis” (MD&A) and provides management’s detailed explanation of the Company’s quarterly financial results, business trends, forward-looking outlook and operational performance for the three months ended March 31, 2026. It does not itself include full financial statements (which are referenced separately) and is not merely an announcement or certification. It matches the definition for Management Reports (Code: MDA).
2026-05-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.